▁Introduction 10.375
: 6.51953125
<0x0A> 3.98046875
In 4.578125
▁a 2.93359375
▁break 7.19140625
through 1.2841796875
▁moment 4.484375
▁in 1.83984375
▁the 1.19140625
▁fight 2.849609375
▁against 0.361572265625
▁cancer 2.466796875
, 0.1307373046875
▁British 5.3125
▁bi 5.07421875
ote 0.4990234375
ch 0.34765625
▁company 0.7880859375
, 2.609375
▁[ 10.015625
Company 4.46875
▁Name 0.681640625
], 0.982421875
▁has 0.85107421875
▁un 3.71484375
ve 0.0828857421875
iled 0.0006532669067382812
▁a 0.9384765625
▁ground 2.87109375
- 0.9423828125
bre 0.0038433074951171875
aking 0.00022399425506591797
▁treatment 2.33984375
▁that 0.8486328125
▁shows 5.59765625
▁remarkable 3.529296875
▁potential 2.427734375
. 3.14453125
▁The 1.421875
▁innov 4.296875
ative 0.32275390625
▁drug 2.703125
▁has 2.82421875
▁already 2.53125
▁demonstrated 3.080078125
▁prom 3.802734375
ising 0.00030112266540527344
▁results 0.31494140625
▁in 0.34375
▁early 3.412109375
▁clin 1.09765625
ical 0.0004582405090332031
▁tri 0.1424560546875
als 0.00010597705841064453
, 0.95166015625
▁raising 6.2265625
▁hope 1.890625
▁for 1.041015625
▁patients 1.8193359375
▁and 3.201171875
▁health 3.37109375
care 0.249267578125
▁profession 0.433349609375
als 0.0002682209014892578
▁al 0.5244140625
ike 2.872943878173828e-05
. 0.23046875
▁However 4.68359375
, 0.004268646240234375
▁while 4.50390625
▁the 0.8349609375
▁initial 3.21484375
▁find 2.3203125
ings 1.0848045349121094e-05
▁insp 9.046875
ire 0.0017957687377929688
▁optim 0.857421875
ism 0.00112152099609375
, 0.1317138671875
▁anal 7.96484375
yst 0.01216888427734375
s 0.0033969879150390625
▁stress 5.94140625
▁the 0.6298828125
▁need 0.262451171875
▁for 0.0872802734375
▁c 8.984375
aut 0.0013723373413085938
ious 0.0031375885009765625
▁optim 0.1893310546875
ism 0.0005278587341308594
▁and 2.26953125
▁further 3.83984375
▁research 1.158203125
▁before 1.4833984375
▁fully 5.12109375
▁end 2.330078125
ors 0.003353118896484375
ing 0.0010356903076171875
▁this 2.7109375
▁potential 3.701171875
▁break 1.5791015625
through 0.0012388229370117188
. 0.2454833984375
<0x0A> 0.369384765625
Prom 7.875
ising 0.09063720703125
▁C 2.904296875
lin 0.007213592529296875
ical 0.0021305084228515625
▁Results 1.2099609375
: 2.3359375
<0x0A> 0.26904296875
[ 2.048828125
Company 0.02740478515625
▁Name 0.01148223876953125
] 0.2320556640625
' 2.255859375
s 0.00650787353515625
▁cancer 5.62109375
▁drug 0.91796875
, 0.97021484375
▁currently 5.96875
▁in 0.7587890625
▁the 2.19921875
▁experimental 5.9296875
▁stage 0.88232421875
, 0.1317138671875
▁has 0.275390625
▁yield 5.69921875
ed 0.001129150390625
▁encourag 1.7216796875
ing 0.00044918060302734375
▁results 0.394775390625
▁in 0.1947021484375
▁pre 2.8125
lim 0.345458984375
inary 0.00016748905181884766
▁tri 1.9580078125
als 5.900859832763672e-05
. 0.358642578125
▁Initial 3.51171875
▁data 2.6171875
▁indicates 2.5625
▁a 2.544921875
▁substantial 5.4609375
▁reduction 0.59716796875
▁in 0.0270843505859375
▁tum 0.499755859375
or 0.662109375
▁size 1.0869140625
▁and 0.666015625
▁improved 3.115234375
▁surv 1.5712890625
ival 0.0004506111145019531
▁rates 0.2296142578125
▁among 2.416015625
▁a 6.015625
▁select 3.16796875
▁group 0.1485595703125
▁of 0.0007834434509277344
▁patients 0.256103515625
. 0.66162109375
▁The 1.8701171875
▁drug 1.28515625
' 1.50390625
s 0.000263214111328125
▁unique 4.359375
▁mechanism 1.1904296875
▁of 0.01290130615234375
▁action 0.0027027130126953125
, 1.9130859375
▁which 1.23046875
▁targets 1.5380859375
▁specific 2.283203125
▁cancer 1.4287109375
▁cells 0.436767578125
▁while 1.65234375
▁sp 0.583984375
aring 0.0019464492797851562
▁health 0.1434326171875
y 0.0006127357482910156
▁t 0.732421875
issues 1.513671875
, 0.04864501953125
▁holds 4.734375
▁significant 2.296875
▁potential 2.17578125
▁for 0.336669921875
▁transform 5.38671875
ing 0.10101318359375
▁cancer 1.8232421875
▁treatment 0.345947265625
▁on 4.75
▁a 0.141845703125
▁global 0.364990234375
▁scale 0.06866455078125
. 0.03314208984375
<0x0A> 0.64013671875
Anal 3.05078125
yst 0.0299530029296875
s 0.33984375
▁Ur 4.44140625
ge 0.007808685302734375
▁Ca 0.1744384765625
ution 0.000522613525390625
: 0.06658935546875
<0x0A> 0.006900787353515625
Des 2.328125
p 0.0005717277526855469
ite 6.639957427978516e-05
▁the 0.44970703125
▁early 3.548828125
▁success 1.3681640625
, 1.90234375
▁exper 3.576171875
ts 5.245208740234375e-06
▁remain 2.41015625
▁c 0.50634765625
aut 3.2067298889160156e-05
ious 0.035797119140625
▁and 3.205078125
▁highlight 5.99609375
▁the 0.3642578125
▁importance 3.908203125
▁of 0.00357818603515625
▁continued 3.1640625
▁research 0.44287109375
▁and 0.81982421875
▁rig 4.21484375
orous 0.0134124755859375
▁testing 1.5078125
. 1.7978515625
▁While 1.1611328125
▁initial 1.705078125
▁clin 3.400390625
ical 0.0004496574401855469
▁results 0.9013671875
▁are 0.394287109375
▁und 7.640625
ou 1.0888671875
bt 0.0003821849822998047
edly 0.004390716552734375
▁prom 0.397705078125
ising 6.0677528381347656e-05
, 0.0096282958984375
▁anal 3.08984375
yst 0.0003094673156738281
s 0.00028061866760253906
▁under 9.3125
line 0.0224151611328125
▁the 0.0292816162109375
▁need 0.277099609375
▁for 0.033935546875
▁statistical 10.7734375
▁significance 3.47265625
▁and 0.88232421875
▁further 1.021484375
▁investig 5.25390625
ations 0.03631591796875
▁to 2.0703125
▁subst 4.359375
anti 2.968311309814453e-05
ate 0.0001691579818725586
▁the 0.68603515625
▁drug 0.7099609375
' 0.00618743896484375
s 0.00017130374908447266
▁effic 1.21484375
acy 8.344650268554688e-06
▁beyond 6.01953125
▁the 1.3115234375
▁limited 5.41796875
▁sample 1.91015625
▁size 0.1727294921875
▁observed 4.96875
▁so 2.443359375
▁far 0.00017893314361572266
. 0.0151824951171875
▁Cont 7.27734375
in 0.11407470703125
ued 0.0028247833251953125
▁evalu 5.8203125
ations 0.00496673583984375
▁of 1.6484375
▁long 7.11328125
- 0.00997161865234375
term 0.0020503997802734375
▁safety 2.158203125
, 2.53515625
▁potential 4.40234375
▁side 0.396728515625
▁effects 0.08477783203125
, 0.340087890625
▁and 0.06500244140625
▁the 2.482421875
▁drug 1.283203125
' 0.0068511962890625
s 0.0007939338684082031
▁effect 2.6875
iveness 0.57080078125
▁against 2.02734375
▁different 2.845703125
▁cancer 1.8935546875
▁types 0.0411376953125
▁are 0.69482421875
▁cru 2.158203125
cial 0.0009250640869140625
▁before 2.0859375
▁drawing 5.09765625
▁any 1.51171875
▁definit 1.736328125
ive 0.00016605854034423828
▁conclus 0.029449462890625
ions 1.3232231140136719e-05
. 0.23486328125
<0x0A> 0.106201171875
Address 8.828125
ing 0.41455078125
▁H 6.64453125
urd 0.08587646484375
les 0.00514984130859375
▁A 4.4375
head 0.005344390869140625
: 0.05731201171875
<0x0A> 0.0038166046142578125
The 2.44921875
▁landscape 8.8828125
▁of 0.28369140625
▁cancer 0.330078125
▁research 1.8642578125
▁is 0.92236328125
▁l 4.69921875
itter 0.03436279296875
ed 0.00018835067749023438
▁with 0.0025615692138671875
▁count 4.68359375
less 3.0159950256347656e-05
▁prom 2.845703125
ising 1.633167266845703e-05
▁ther 2.939453125
ap 0.002773284912109375
ies 6.73532485961914e-05
▁that 0.314697265625
▁failed 3.0
▁to 0.059173583984375
▁deliver 1.251953125
▁upon 4.7109375
▁further 8.2265625
▁exam 3.908203125
ination 0.003185272216796875
. 0.2822265625
▁Anal 3.189453125
yst 0.00048732757568359375
s 0.0008692741394042969
▁and 4.98046875
▁industry 3.255859375
▁ins 2.154296875
iders 0.0020847320556640625
▁agree 3.4921875
▁that 0.06402587890625
▁the 1.2724609375
▁road 3.970703125
▁ahead 0.37109375
▁remains 2.103515625
▁challeng 1.626953125
ing 0.0009336471557617188
. 3.248046875
▁The 2.677734375
▁drug 1.9912109375
' 0.357666015625
s 0.00011551380157470703
▁effic 3.4609375
acy 1.9431114196777344e-05
▁must 2.349609375
▁be 0.040313720703125
▁demonstrated 2.97265625
▁across 2.669921875
▁larger 4.421875
▁patient 1.1884765625
▁coh 2.294921875
ort 9.894371032714844e-06
s 0.0007152557373046875
▁to 2.458984375
▁determine 3.669921875
▁whether 1.751953125
▁the 1.9970703125
▁initial 2.984375
▁success 1.92578125
▁stories 8.1171875
▁can 2.501953125
▁be 0.16650390625
▁rep 0.42431640625
licated 0.0022106170654296875
▁consist 5.84375
ently 0.00010609626770019531
. 0.290283203125
▁Furthermore 3.068359375
, 0.00021660327911376953
▁regul 4.40234375
atory 0.196044921875
▁appro 1.5166015625
val 3.218650817871094e-05
▁processes 3.6328125
, 3.876953125
▁pr 5.42578125
icing 0.038482666015625
▁challeng 4.0859375
es 7.3909759521484375e-06
, 0.03509521484375
▁and 0.0771484375
▁access 3.408203125
▁to 2.216796875
▁the 2.0078125
▁treatment 2.404296875
▁for 3.89453125
▁all 2.048828125
▁patients 0.8623046875
▁will 2.55078125
▁require 3.037109375
▁careful 2.162109375
▁consideration 1.1416015625
. 0.65966796875
<0x0A> 0.40283203125
Import 6.6484375
ance 0.81884765625
▁of 0.1163330078125
▁Coll 4.2890625
abor 0.00020253658294677734
ative 2.0
▁E 1.69921875
ff 0.00036263465881347656
ort 3.170967102050781e-05
s 0.037689208984375
: 0.0755615234375
<0x0A> 0.0014972686767578125
To 5.19140625
▁ensure 2.607421875
▁progress 5.4140625
▁in 2.125
▁cancer 1.7255859375
▁research 0.257568359375
, 0.41552734375
▁collabor 2.806640625
ative 0.06634521484375
▁efforts 0.025360107421875
▁among 2.201171875
▁scient 2.77734375
ists 0.0006098747253417969
, 0.237060546875
▁medical 3.669921875
▁profession 0.326416015625
als 7.748603820800781e-06
, 0.0164642333984375
▁regul 3.767578125
atory 1.291015625
▁bodies 0.6494140625
, 0.0302886962890625
▁and 0.2132568359375
▁fund 3.005859375
ing 0.29150390625
▁ag 0.65771484375
encies 0.0002282857894897461
▁are 0.2440185546875
▁essential 1.5146484375
. 0.06353759765625
▁A 3.93359375
▁un 2.513671875
ited 0.75732421875
▁front 0.371337890625
▁allows 6.01953125
▁for 0.436279296875
▁the 1.6259765625
▁highest 7.58984375
▁standards 3.1171875
▁of 0.27294921875
▁scr 6.234375
ut 0.0005235671997070312
iny 0.004665374755859375
, 1.390625
▁thus 7.703125
▁mit 5.05859375
ig 6.4373016357421875e-06
ating 0.0006537437438964844
▁any 3.318359375
▁potential 1.1806640625
▁ris 1.5361328125
ks 0.00035381317138671875
▁or 2.791015625
▁mis 3.96484375
inter 2.748046875
pret 0.0177001953125
ation 1.4658203125
▁of 0.232177734375
▁prom 4.21484375
ising 2.3365020751953125e-05
▁data 2.49609375
. 0.0699462890625
▁Anal 3.578125
yst 0.0004940032958984375
s 0.00156402587890625
▁assert 5.70703125
▁that 0.106201171875
▁such 2.84375
▁collabor 2.287109375
ations 1.6669921875
▁will 1.443359375
▁be 1.1982421875
▁p 4.21875
iv 7.069110870361328e-05
otal 2.1338462829589844e-05
▁in 0.49609375
▁navig 5.3203125
ating 5.125999450683594e-05
▁the 0.446533203125
▁complex 1.322265625
▁journey 5.06640625
▁from 3.2421875
▁experimental 5.16796875
▁phases 7.78515625
▁to 0.10498046875
▁approved 4.11328125
, 6.0546875
▁accessible 2.546875
▁treat 1.23046875
ments 3.075599670410156e-05
. 0.83447265625
<0x0A> 0.09014892578125
Pat 7.0703125
ient 0.30810546875
▁Imp 3.810546875
act 0.123291015625
▁and 4.8359375
▁Future 3.5859375
▁Pers 3.958984375
pect 0.372314453125
ives 7.271766662597656e-06
: 0.05877685546875
<0x0A> 0.0021266937255859375
Und 8.171875
ou 0.26904296875
bt 0.0003504753112792969
edly 0.0010957717895507812
, 0.216552734375
▁the 0.6455078125
▁potential 2.283203125
▁break 4.29296875
through 0.0003895759582519531
▁in 2.09765625
▁cancer 0.63134765625
▁treatment 0.51611328125
▁show 8.21875
c 0.76123046875
ased 0.0030536651611328125
▁by 0.09881591796875
▁[ 0.1331787109375
Company 0.00698089599609375
▁Name 0.00482940673828125
] 0.0173187255859375
' 3.2890625
s 0.0031108856201171875
▁drug 0.603515625
▁inst 10.15625
ig 2.5859375
ates 0.06787109375
▁hope 0.49658203125
▁among 2.033203125
▁patients 0.291259765625
, 2.5390625
▁care 4.21484375
g 0.03350830078125
ivers 0.0007171630859375
, 0.00844573974609375
▁and 0.12408447265625
▁health 0.50048828125
care 0.03375244140625
▁prov 3.02734375
iders 0.00012111663818359375
▁world 4.953125
wide 0.0011425018310546875
. 0.0107421875
▁However 1.7099609375
, 0.00040793418884277344
▁anal 2.810546875
yst 0.0007257461547851562
s 0.0007100105285644531
▁emphas 2.791015625
ize 0.0197296142578125
▁the 0.1893310546875
▁importance 1.8095703125
▁of 0.0039215087890625
▁man 9.3671875
aging 0.002849578857421875
▁expect 0.242919921875
ations 0.0001068115234375
▁while 2.724609375
▁understanding 5.1953125
▁that 1.2607421875
▁research 5.6171875
▁and 1.3154296875
▁development 0.57470703125
▁in 3.640625
▁the 1.314453125
▁field 0.802734375
▁of 0.943359375
▁on 0.88330078125
col 0.00438690185546875
ogy 0.00023174285888671875
▁is 0.99462890625
▁an 2.431640625
▁intr 5.484375
icate 0.0260467529296875
▁process 1.0078125
▁that 1.146484375
▁requires 1.4189453125
▁time 2.955078125
▁and 0.99365234375
▁careful 2.662109375
▁evaluation 2.83203125
. 0.32470703125
▁Cont 5.86328125
in 0.07208251953125
ued 0.00887298583984375
▁support 4.10546875
▁and 1.03125
▁invest 2.05078125
ments 2.19921875
▁in 0.96337890625
▁cutting 4.50390625
- 0.007114410400390625
edge 0.0012292861938476562
▁research 0.96923828125
, 3.0703125
▁couple 4.10546875
d 0.0001392364501953125
▁with 0.000431060791015625
▁a 2.609375
▁patient 3.0859375
- 0.046142578125
orient 4.31640625
ed 0.03753662109375
▁approach 0.3994140625
, 0.32080078125
▁will 0.52197265625
▁be 2.109375
▁cru 1.748046875
cial 0.0001627206802368164
▁to 1.1533203125
▁capital 7.86328125
ize 1.5703125
▁on 0.0389404296875
▁the 0.7373046875
▁significant 3.25
▁progress 3.431640625
▁achieved 4.16796875
▁and 4.83984375
▁ultimately 4.15234375
▁offer 5.3046875
▁improved 3.267578125
▁treatment 1.6669921875
▁options 0.34228515625
▁to 0.9697265625
▁cancer 0.99609375
▁patients 0.05352783203125
▁glob 4.23046875
ally 3.504753112792969e-05
. 0.010772705078125
<0x0A> 0.0675048828125
Con 5.40234375
clusion 0.43896484375
: 0.2152099609375
<0x0A> 2.96484375
[ 2.068359375
Company 0.023040771484375
▁Name 0.0063629150390625
] 0.176513671875
' 0.268310546875
s 0.00214385986328125
▁cancer 1.830078125
▁drug 0.4560546875
▁represents 2.796875
▁an 1.509765625
▁exc 0.95703125
iting 1.2159347534179688e-05
▁development 2.44140625
▁in 0.21044921875
▁the 0.26171875
▁battle 3.708984375
▁against 0.01739501953125
▁this 3.181640625
▁dev 1.392578125
ast 0.00014925003051757812
ating 0.0006918907165527344
▁disease 0.053863525390625
. 0.2010498046875
▁Although 4.6171875
▁initial 1.6123046875
▁clin 1.17578125
ical 0.00017011165618896484
▁tri 1.6650390625
als 1.2993812561035156e-05
▁have 0.74658203125
▁shown 1.455078125
▁great 4.80859375
▁promise 0.130615234375
, 0.08697509765625
▁anal 2.484375
yst 0.00027108192443847656
s 0.0002307891845703125
▁stress 1.4794921875
▁the 0.028533935546875
▁importance 1.34765625
▁of 0.0010852813720703125
▁pr 8.1328125
ud 1.912109375
ence 0.18505859375
▁and 0.34033203125
▁further 1.7705078125
▁investigation 2.146484375
▁before 0.80859375
▁making 2.685546875
▁confident 7.6953125
▁claims 2.568359375
▁about 1.0908203125
▁the 0.509765625
▁drug 0.53857421875
' 0.021575927734375
s 0.00021529197692871094
▁effic 0.6650390625
acy 7.271766662597656e-06
. 0.478515625
▁As 3.744140625
▁the 1.40625
▁medical 5.3515625
▁community 0.796875
▁moves 4.05859375
▁forward 0.69775390625
, 1.314453125
▁on 6.109375
going 1.4541015625
▁collabor 1.9599609375
ations 1.24609375
, 3.39453125
▁rig 1.41796875
orous 0.00432586669921875
▁testing 1.1533203125
, 0.043701171875
▁and 0.041229248046875
▁thorough 5.80078125
▁evaluation 1.4912109375
▁will 0.91552734375
▁play 3.6640625
▁a 0.236328125
▁vital 2.01953125
▁role 0.006076812744140625
▁in 0.0103912353515625
▁transform 3.65234375
ing 0.004150390625
▁a 7.59765625
▁potential 4.3984375
▁break 0.275146484375
through 0.0002111196517944336
▁into 0.043609619140625
▁a 0.76708984375
▁genu 6.17578125
ine 0.296875
▁life 3.35546875
- 0.0151519775390625
s 0.95263671875
aving 0.0016012191772460938
▁treatment 0.4541015625
▁for 1.3564453125
▁cancer 0.4345703125
▁patients 0.038421630859375
▁world 0.8349609375
wide 0.0002378225326538086
. 0.0102691650390625
